Home Blog Page 267

Experts call to ban the school bake sale

Allergies and food hygiene mean that charity sales are OVER – or are they?

We’re a country of cake-lovers, but it really is time to think the unthinkable and ban the school bake sale.

That’s the opinion of a British health and safety software company which thinks that the goodwill of buying and scoffing a home-baked treat for a good cause is outweighed by the risks of the DANGER CAKE.

But Protecting.co.uk denies pandering to the so-called (and probably non-existent) snowflake generation.

“Nobody wants food poisoning,” says company spokesperson Mark Hall, “Concern for the dangers is often mistaken for snowflakery by people who didn’t mind the odd case of the squirts back in the day.

“Times have changed for the better,” he says, “but don’t worry – we have a genius solution too.”

What’s your beef with cakes, then?

On the contrary, Protecting.co.uk likes cake just as much as the next person. We could eat cake and down a nice cup of tea until the cows come home.

The problem comes with school, scout hut, or charity bake sales where you don’t know where the food’s come from, and how clean was the kitchen where it was prepared.

“One person’s spotlessly clean kitchen is another person’s food poisoning death trap,” says Protecting’s Mark Hall.

“We have first-hand experience of a local amateur cake enthusiast who claims his kitchen is perfectly clean. And it is – apart from the pet cats he allows to strut all over the work surfaces and we doubt very much that anyone baking cakes at home has an food hygiene certificate.

“We’ve also heard of school cake sales where over-enthusiastic young members of the home economics class claim to have spat in the mix before slapping it into the oven. Urban myth? Who knows?”

“And there’s also a major problem for people with allergies,” says Mark Hall. “The label may say ‘free of nuts’, ‘gluten free’, or ‘dairy free’ but how do you really know?”

The question of allergies – which can cause a life-threatening health reaction – is a stark reminder of the risks of consuming food from a questionable, if well-meaning, source.

Why shut down these well-meaning events?

Commercial kitchens come with very strict sets of regulations designed to protect customers from food poisoning and the accidental serving of allergens.

There are rules for preparation areas, rules for the storing of raw and cooked products, and rules for the personal cleanliness of kitchen staff.

“These rules and regulations exist for the protection of the public, and nobody in their right mind has a problem with them,” says Mark.

“So why do people happily go out and buy food products from a random kitchen in somebody’s house where these controls don’t exist?”

“Down with this sort of thing, we say.”

Could there be an alternative? Why, yes there is

We’re a company that works by finding solutions to people’s workplace problems, so of course we have a solution to this – and it lies in the phenomenon on the Cake Sale Cheat.

We all know that smug parent who traipses in on the day with a beautiful creation that would not be out of place on The Great British Bake Off.

And that’s because they’ve bought it in a shop, taken it out of the box, and presented it at school, the scout hut or community hall as their own work.

So, instead of staring at them accusingly and saying things like “Who does she think she is, Mary Berry?”, let’s grasp the example of the Cake Sale Cheat, and all do it.

Everybody should buy a cake, bring it to the cake sale in its original packaging complete with allergy advice and ingredients list, and everybody knows what they’re buying.

And all that’s left for Cake Sale Cheat is to buy a really expensive cake to give away to the school, because those are the new rules we’ve just made up.

“Everybody’s a winner,” says Mark Hall. “The cake sale wins, the cake shop wins, and all of us – the people who called out the Cake Sale Cheats – we win as well.”

“Have your cake AND eat it, that’s what we say.”

Why Doesn’t the NHS take Testosterone Deficiency Seriously?

Testosterone Deficiency is a well-recognised medical condition. In the UK there are British Society for Sexual Medicine guidelines for its diagnosis and management.   The Society of Endocrinology defines the condition:-

“Hypogonadism is defined as a clinical syndrome complex that comprises symptoms and signs as well as biochemical evidence of testosterone deficiency.”

The inception of The Men’s Health Clinic was inspired by an appreciation that Testosterone Deficiency is a poorly understood, under-recognised and under-appreciated health concern.  Terms such as the “Manopause” and Andropause which compare low testosterone to the female menopause are unhelpful and trivialise the condition.  The pathological mechanism that causes low testosterone is very distinct from the female menopause, which is a defined period in a female’s timeline when she no longer ovulates, her periods cease and her oestrogen lowers.  The misassociation may be in part due to the fact that oestrogen is considered the female sex-hormone and testosterone is considered the male sex-hormone. This is also misleading as men and women need both testosterone and oestrogen for overall health and well-being. In men, testosterone is converted to oestradiol by the aromatase enzyme. Oestrogen is integral for cardiovascular health, bone strength, brain function and fertility.

Testosterone Deficiency has been trivialised by the media.  In fact, men’s health in general has been over-looked and dismissed by everyone, including men. It’s only recently, that the importance of testosterone in physical and psychological health is being fully appreciated. Unfortunately, the NHS places a greater emphasis on a curative medical model for several reasons; it’s under-financed and under-resourced, used and abused by all and sundry based on a false sense of entitlement. The NHS is used as a sacrificial political pawn, politicians subtly manipulate the general public with false claims and promises.  Prevention is fundamental to sustainable positive health outcomes, but when finances are diverted to firefighting rather than addressing foundations, causation is a secondary consideration.  Budgets need to demonstrate outcomes.

Testosterone has long been associated with Bodybuilding and athletes abusing the anabolic effects of the hormone.  The use of testosterone and other Androgenic Anabolic Steroids (AAS) has seeped into mainstream culture, with men not fully understanding the long-term consequences of abuse.  AAS are a common cause of Testosterone Deficiency.  Post Cycle Therapy (PCT) is not a reliable method of reigniting your Hypo-pituitary Gonadal (HPG) axis, nature often defies science.  Anabolic steroids have a place in medicine, they were designed to help with patients suffering with chronic wasting diseases, immunocompromised and cancer patients.  However, doctors appear to have an aversion to anything testosterone related, believing that the reported negative symptoms are simply an excuse for attaining a beach body or an unfair competitive edge.

GPs have 10-minute appointments, most see about 40 patients a day, from coughs and colds to cancer to mental health and social issues to… It’s no wonder the negative symptoms of low testosterone are often dismissed in an otherwise healthy looking male.  Men are often either offered antidepressants for their low mood and/or Viagra for their low libido and erectile dysfunction. Doctors have a curative rather than preventative mindset because they simply do not have the time to address causation.

Education is fundamental to implementing sustainable change.  Men have turned to the internet for guidance. We have access to everything and anything, communities have arisen, some positive like TRT in the UK; and some bad that offer false promises, simply feeding confirmation bias.  Testosterone is marketed as a lifestyle drug, not a medical treatment to treat a medical condition. This must end.

Dr Robert Stevens MBChB MRCGP Dip.FIPT

This is how much TV we will watch in a lifetime

The average TV fan will sit through an eye-popping 78,705 hours of soaps, sports, news, movies and box sets during their lifetime, a study has found.

A poll of 2,000 adults revealed that an average of three-and-a-half hours a day is spent watching television – a total of 1,248 hours a year.

Over the average adult lifetime, this will mean TV fans will immerse themselves in 3,639 films in the comfort of their own home, as well as watching a staggering 31,507 episodes of TV shows.

But the average household will have two arguments a week over what to watch and more than half of those polled would struggle if they only had one TV between them.

As a result, the research by LG Electronics found the typical British home has two TVs, upgrading their set every six years on average.

It also emerged a quarter of those polled said their viewing experience is ‘ruined’ by the quality of their TV, so they will often venture elsewhere, such as a friend’s house or the pub, in search of a superior screen.

 

James Thomas, home entertainment product manager at LG UK said: “The Golden Age of Content is here, but similar to the golden age of film and cinema, it won’t be fully appreciated until it’s over.

“Everyone has a favourite series to sink into at the end of a day, but many are missing out on the full experience due to the limitations of an old TV.”

The study also found that six in 10 adults went as far as to say they would be lost without their television set.

But poor sound quality and glare on the screen are among the nation’s biggest bugbears.

People talking over a favourite show, others asking questions and poor visual quality were also among the greatest annoyances, according to the OnePoll research.

Fifteen per cent also said they get frustrated by having too much choice, with adults spending an average of 2,943 hours over their lifetime browsing and deciding what to watch.

And following a decision, they will watch 11,278 different series over a lifetime – whether that’s just one episode or an entire boxset.

After revealing the nation’s love of TV, LG partnered with Realeyes – the world’s leading ‘emotion AI’ company – to conduct an experiment on identical twins which compared the differences between physical and emotional response when watching Game of Thrones on a 2019 LG OLED TV verses a 2013 LED TV.

The experiment was performed on identical twin social media influencers, Henry and William Wade, at the LG UK test facility in Weybridge.

The twins were separated into blacked-out TV immersion rooms where they simultaneously watched ‘The Battle of the Bastards’ – IMDB’s highest-rated Game of Thrones episode – on the different TVs.

William watched on a 2019 set, while Henry viewed a 2013 TV, representing the most common type of TV in homes across the UK.

Realeyes’ AI platform analysed the facial expressions, head movements and body language from more than 144,000 frames of video footage captured of each twin.

Their physical responses were also measured using heart rate monitors.

The results revealed the 2019 OLED TV held 25 per cent more attention than the 2013 LED, and throughout the episode, 27 emotional peaks were observed on the newer TV compared to just four peaks on the older model.

Happiness, which in the context of the experiment was linked to level of entertainment, was also three times higher.

Overall, the 2019 TV provided a 15 per cent more intense experience from a positive emotional standpoint.

Mihkel Jäätma, CEO and co-founder of Realeyes, said: “This experiment by LG was a really interesting and fun way to utilise our ground-breaking AI technology.

“We’ve taught computers to read and understand human emotions and attention, which allows us to offer scientifically sound measurements of a viewer’s immersion.”

3 Simple But Effective Home Safety Tips for Seniors

From the United Kingdom to the United States, many countries are growing older. According to the August 2019 population overview from the Office for National Statistics, about one in every five people in the UK is above the age of 65, with the percentage increasing every year.

In short, the Baby Boomer generation is, in increasing numbers, reaching retirement age, with a growing number of seniors opting to stop working and enjoy their lives outside of their careers. 

With a large percentage of the newly retired opting not to downsize to smaller homes, many of the UK’s retirees are likely to spend the last decades of their lives living inside the same homes that they raised their children in — homes that, in many cases, aren’t designed for seniors. 

This brings with it some safety concerns, from the risks associated with stairs to the sheer work that’s involved in maintaining a large home. If you parents, grandparents or other senior people that you care about live alone in their family home, you can help them to stay safe.

Below, we’ve shared three simple but effective home safety tactics that you can use to make life safer, easier and more comfortable for your parents or grandparents, allowing them to maintain their independence while staying safe and secure throughout retirement. 

Make Sure Their Bathroom is Safe

If you’re a caregiver for seniors, or simply want to make sure that your aging parents are safe, it can help to start by checking their bathrooms for safety hazards.

Bathrooms can be risky spaces, particularly for seniors. Wet surfaces can often lead to falls and painful injuries — injuries that can affect everything from mobility to mental health. 

Good bathroom safety tactics include adding a grab bar in the shower to reduce the risk of a slip or fall. It can also help to install a rubber mat, or switch from a combined bathtub and shower to a less risky walk-in shower design.

Other ideas include installing night lighting, which can make it easier to navigate the bathroom in the dark, and adding either a sitting surface or a bathing chair to the shower area to ensure that mobility doesn’t interfere with bathing. 

Identify and Remove Fire Hazards

Fires can start alarmingly quickly, with something as small as a stray candle or as normal as a forgotten-about oven all it takes to start a blaze that can damage a home and put the safety of its occupants at risk.

If you’re concerned about fire risks inside a senior’s home, check for potential fire hazards and take steps to mitigate them. This can include checking electrical cords and removing anything that’s frayed or otherwise damaged, or checking for hazards close to ovens and heaters. 

If your parents’ or grandparents’ home contains cooking equipment that can spit grease around the kitchen, consider asking them to avoid using it or replace it with a safer option. 

Pots, deep fryers, pans and other cooking equipment rank among the most common sources of house fires, making it worth bringing up if you have concerns about a loved one’s safety. It can also help to check for fire risks, such as towels or tissues, placed close to hot items. 

Make Using the Stairs Safer

While stairs are rarely a hazard for healthy retirees in their 70s, they can be a significant safety risk for seniors in their 80s and 90s. As such, if your parents or grandparents live in a home with stairs, it’s important to make them as safe as possible.

By far the most effective way to make stairs safer, particularly for seniors with injuries or issues walking up and down the stairs frequently, is to install a stairlift. This allows even someone with significant mobility issues to use the stairs with a far lower risk of falls or other injuries.

If a stairlift isn’t economically feasible, or if you think it isn’t necessary, there are still steps that you can take to make the stairs safer. Check that they’re finished in a material that provides a great deal of grip, even if it’s wet or dusty. 

It’s also important to make sure that the stairs are visually differentiated. Many slips, falls and other injuries involving stairs occur in the evening and at night, when it can be difficult for those with partial vision to clearly see where one step ends and the next begins.

Earnings Recap: Green Plains Inc. (NASDAQ: GPRE)

OMAHA, Neb., November 27, 2019 – Shares of Green Plains Inc. (NASDAQ: GPRE) lost -0.13% to $15.20. The stock traded total volume of 394.547K shares lower than the average volume of 777.11K shares.

Green Plains Inc. (GPRE) reported net loss attributable to the company of $45.30M, or $(1.13) per diluted share, for the second quarter of 2019 compared with net loss of $1.00M, or $(0.02) per diluted share, for the same period in 2018. Revenues were $895.90M for the second quarter of 2019 compared with $986.80M for the same period last year.

Revenues attributable to the company were $1.50B for the six-month period ended June 30, 2019, compared with $2.00B for the same period in 2018. Net loss for the six-month period ended June 30, 2019, was $88.10M, or $(2.19) per diluted share, compared with net loss of $25.10M, or $(0.63) per diluted share, for the same period in 2018.

Results of Operations:

Green Plains produced 224.00M gallons of ethanol during the second quarter of 2019, compared with 296.30M gallons for the same period in 2018. The consolidated ethanol crush margin was $19.90M, or $(0.09) per gallon, for the second quarter of 2019, compared with $25.60M, or $0.09 per gallon, for the same period in 2018. The consolidated ethanol crush margin is the ethanol production segment’s operating income (loss) before depreciation and amortization, which includes corn oil, plus intercompany storage, transportation and other fees, net of related expenses.

Consolidated revenues of $895.90M decreased $91.00M for the three months ended June 30, 2019, compared with the same period in 2018, due primarily to the disposition of three ethanol plants and the sale of Fleischmann’s Vinegar during the fourth quarter of 2018, offset by increased cattle volumes sold due to the acquisition of two feed lots in the third quarter of 2018.

Operating loss for the three months ended June 30, 2019 was $39.40M, compared with operating income of $11.80M for the same period last year, primarily due to decreased margins on ethanol production as well as the disposition of Fleischmann’s Vinegar during the fourth quarter of 2018. Interest expense decreased $6.10M to $16.00M for the three months ended June 30, 2019 compared with the same period in 2018, primarily due to the repayment of the $500.0M senior secured term loan during the fourth quarter of 2018. Income tax benefit was $14.70M for the three months ended June 30, 2019 compared with $10.80M for the same period in 2018.

Earnings before interest, income taxes, depreciation and amortization (EBITDA) for the second quarter of 2019 were $19.80M compared with $41.80M for the same period last year.

GPRE has the market capitalization of $528.81M and its EPS growth ratio for the past five years was -19.10%. The return on assets ratio of the Company was -3.60% while its return on investment ratio stands at 7.20%. Price to sales ratio was 0.18.

An Eye on Financial Results: Clearway Energy Inc. (NYSE: CWEN)

For the second quarter of 2019, Clearway Energy Inc. (NYSE: CWEN) reported a net loss of $36.0M, Adjusted EBITDA of $278.0M, Cash from Operating Activities of $89.0M, and CAFD of $68.0M, which includes adjustments to reflect CAFD generated by unconsolidated investments that are unable to distribute project dividends due to the PG&E bankruptcy. Net Income was lower than the second quarter of 2018 due to non-cash changes in the fair value of interest rate swaps, a non-cash asset impairment charge in the Thermal segment, weaker renewable energy conditions, and the June outage at the CVSR facility. Adjusted EBITDA results were lower than 2018 primarily due to weaker renewable energy conditions and the CVSR outage, but partially offset by the contribution of growth investments. In the second quarter, CAFD results were lower than 2018 primarily due to lower Adjusted EBITDA and the expiration of network upgrade reimbursements.

Liquidity and Capital Resources:

Total liquidity as of June 30, 2019 was $746.0M, $291.0M lower than as of December 31, 2018. This reduction was primarily due to the repayment, with cash on hand, of $220.0M in outstanding 2019 Convertible Notes, $19.0M for the buyout of the Wind TE HoldCo tax equity partnership in January 2019, and $27.0M for growth investments, including Duquesne, Mylan, Hawaii Solar Phase I, and ongoing contributions to the DG Investment Partnerships. Borrowing capacity under the revolving credit facility was reduced by $4.0M due to the issuance of corporate letters of credit.

The Company’s liquidity includes $203.0M of restricted cash balances as of June 30, 2019. Restricted cash consists primarily of funds to satisfy the requirements of certain debt arrangements and funds held within the Company’s projects that are restricted in their use. As of June 30, 2019, these restricted funds were comprised of $60.0M designated to fund operating expenses, approximately $45.0M designated for current debt service payments, and $42.0M of reserves for debt service, performance obligations and other items including capital expenditures. The remaining $56.0M is held in distribution accounts, of which $36.0M related to subsidiaries affected by the PG&E bankruptcy.

Potential future sources of liquidity include excess operating cash flow, the existing ATM program, of which $36.0M remained available as of August 6, 2019, availability under the revolving credit facility, and, subject to market conditions, new corporate financings.

2019 Financial Guidance:

The Company is reducing its 2019 full year CAFD guidance to $250.0M to account for the previously disclosed impact of the CVSR outage in June and year to date renewable resource performance. This financial guidance assumes that all CAFD related to the projects impacted by the PG&E Bankruptcy is realized in 2019 and Mylan and Hawaii Solar Phase I achieve target commercial operational dates. Financial guidance for 2019 also continues to be based on median renewable energy production estimates for the remainder of the year.

Hot Stock under Consideration: Celldex Therapeutics Inc. (NASDAQ: CLDX)

Hampton, New Jersey, November 14, 2019 – Shares of Celldex Therapeutics Inc. (NASDAQ: CLDX) plunged -2.58% to $2.27. The stock grabbed the investor’s attention and traded 95.519K shares as compared to its average daily volume of 139.88K shares. The stock’s institutional ownership stands at 25.70%.

Celldex Therapeutics (CLDX) posted revenues of $0.720M for the quarter ended June 2019, missing the Zacks Consensus Estimate by 43.25%. This compares to year-ago revenues of $2.760M. The company has topped consensus revenue estimates two times over the last four quarters. The company came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.65 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 28.21%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.14 per share when it actually produced a loss of $1.13, delivering a surprise of 0.88%.

CLDX has a market value of $33.32M while its EPS was booked as $-3.72 in the last 12 months. The stock has 14.00M shares outstanding. Beta value of the company was 3.44; beta is used to measure riskiness of the security. Analyst recommendation for this stock stands at 2.00.

Today’s Hot Stock Under Review: SVMK Inc. (NASDAQ: SVMK)

SAN MATEO, Calif., October 22, 2019 – Shares of SVMK Inc. (NASDAQ: SVMK) gained 0.57% to $17.57. The stock grabbed the investor’s attention and traded 715.147K shares as compared to its average daily volume of 1.35M shares. The stock’s institutional ownership stands at 77.90%.

SurveyMonkey Inc. (SVMK) reported revenue of $68.60M for 17% year-over-year growth. Paying users totaled 670.862K compared to 610.457K in Q1 2018, for 10% year-over-year growth, and up 24.135K paying users from Q4 2018, for 4% quarter-over-quarter growth. Approximately 78% of our paying users were on annual plans, up from 75% in Q1 2018 and 77% in Q4 2018. Average revenue per user was $423 compared to $390 in Q1 2018, for 8% year-over-year growth, and down slightly from $425 in Q4 2018. Enterprise sales revenue was approximately 16% of total revenue, up from approximately 13% in Q4 2018. We ended the quarter with 3,909 enterprise sales customers, up from 2,838 in Q1 2018, for 37% year-over-year growth, and an increase of 343 customers from Q4 2018.

GAAP net loss was $17.80M and Adjusted EBITDA was $8.50M. GAAP basic and diluted net loss per share was ($0.14). Non-GAAP basic and diluted net loss per share was ($0.02).  Net cash provided by operating activities was $7.80M and unlevered free cash flow was $7.50M, for an 11% margin.

Cash and cash equivalents was $165.90M and total debt was $216.90M for net debt of $51.00M. Subsequent to Q1 2019, our acquisition of Usabilla resulted in a net cash outlay of approximately $53.0M.

SVMK has a market value of $2.46B while its EPS was booked as $-1.48 in the last 12 months. The stock has 140.16M shares outstanding. In the profitability analysis, the company has gross profit margin of 71.50% while net profit margin was -59.20%. Analyst recommendation for this stock stands at 2.00.

Active Stock Evaluation: SeaSpine Holdings Corporation (NASDAQ: SPNE)

CARLSBAD, Calif., October 21, 2019 – Shares of SeaSpine Holdings Corporation (NASDAQ: SPNE) inclined 3.36% to $11.38. The stock traded total volume of 41.570K shares lower than the average volume of 44.36K shares.

For the first quarter of 2019, SeaSpine Holdings Corporation (SPNE) reported total revenue of $36.20M, a 9% increase compared to the same period of the prior year. Total U.S. revenue was $32.00M, an 8% increase compared to the same period of the prior year.  The increase in U.S. revenue was driven by both the spinal implants and orthobiologics portfolios.  International revenue was $4.20M, a 15% increase compared to the same period of the prior year.  The increase in international revenue was driven primarily by spinal implants growth in Europe.

Orthobiologics revenue totaled $19.00M, a 6% increase compared to the first quarter of 2018.  The increase in orthobiologics revenue was driven primarily by growth in recently launched products, led by the OsteoStrand™ Plus product.

Spinal implants revenue totaled $17.10M, a 13% increase compared to the first quarter of 2018.  The increase in spinal implants revenue was driven by growth in recently launched products, led primarily by the Shoreline and Mariner systems and by the Company’s expanded NanoMetalene portfolio.

Operating expenses for the first quarter of 2019 totaled $31.60M, compared to $28.00M for the same period of the prior year. The $3.60M increase in operating expenses was primarily the result of $2.80M in higher selling, general and administrative expenses, including stock-based compensation related to the timing of equity award grants, selling commissions, and salaries and wages.  Research and development costs increased approximately $0.70M primarily due to increased headcount and higher costs related to clinical studies.

Net loss for the first quarter of 2019 was $9.00M, compared to a net loss of $7.10M for the same period of the prior year.

Cash, cash equivalents and investments at March 31, 2019 totaled $45.00M and the Company had no amounts outstanding under its credit facility.

Updated 2019 Financial Outlook:

SeaSpine expects full-year 2019 revenue to be in the range of $154.0M to $156.0M, reflecting growth of approximately 7.5% to 9.0% over full-year 2018 revenue. This compares to previous revenue guidance of $152.0M to $156.0M.

SPNE has the market capitalization of $209.85M and its EPS growth ratio for the past five years was 1.40%. The return on assets ratio of the Company was -25.60% while its return on investment ratio stands at -23.40%. Price to sales ratio was 1.41 while 60.80% of the stock was owned by institutional investors.

News Review: SRC Energy Inc. (NYSE: SRCI)

DENVER, October 21, 2019 – Shares of SRC Energy Inc. (NYSE: SRCI) declined -6.50% to $3.45. The stock grabbed the investor’s attention and traded 6.363M shares as compared to its average daily volume of 5.69M shares.

SRC Energy Inc. (NYSE American: SRCI) reported first-quarter profit of $49.80M. On a per-share basis, the Denver-based company said it had profit of 20 cents. Earnings, adjusted for non-recurring costs, came to 27 cents per share. The results surpassed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 24 cents per share.

The oil and gas company posted revenue of $189.50M in the period, also beating Street forecasts. Eleven analysts surveyed by Zacks expected $178.20M.

SRCI has a market value of $898.41M while its EPS was booked as $1.02 in the last 12 months. The stock has 260.41M shares outstanding. In the profitability analysis, the company has gross profit margin of 84.90% while net profit margin was 35.40%. Beta value of the company was 1.52; beta is used to measure riskiness of the security. Analyst recommendation for this stock stands at 2.00.

Latest Articles